Author

P. Mali

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:gene regulatory network inference· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Dailamy· 2 shared A. Kumar· 2 shared A. Portell· 2 shared A. Suhardjo· 2 shared Y. Xiang· 2 shared A. Brown· 1 shared A. Deshpande· 1 shared A. J. Deshpande· 1 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

A. Dailamy

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC

Y. Goto, K. Koshizuka, T. Ando, H. Izumi, X. Wu, K. Ford, X. Feng, Z. Wang, N. Arang, M. M. Allevato, A. Kishore, P. Mali, J. S. Gutkind

This study identifies mTOR inhibition as a way to prevent adaptive resistance to CDK4/6 blockade in HNSCC by targeting cell cycle pathways.

bioRxiv · Aug 7, 2023Cancer Biology

High Density Domain-Focused CRISPR Screens Reveal Novel Epigenetic Regulators of HOX/MEIS Activation in Acute Myeloid Leukemia

K. Barbosa, A. Deshpande, M. E. Perales, P. Xiang, R. Murad, A. Minkina, N. A. Robertson, F. Schischlik, X. Lei, Y. Sun, A. Brown, D. Amend, I. Jeremias, J. G. Doench, K. Humphries, , A. J. Deshpande

The paper identifies SGF29 as a novel chromatin regulator of MEIS1 and AML oncogenes, showing its role in leukemogenesis and potential as a drug target.

bioRxiv · Dec 12, 2022 · PreprintCancer Biology

Reprogramming Adeno-Associated Virus Tropism Via Displayed Peptides Tiling Receptor-Ligands

A. Portell, K. M. Ford, A. Suhardjo, J. Rainaldi, M. N. Bublik, M. Sanghvi, A. Kumar, M. K. Wing, N. D. Palmer, D. A. Le, N. Kalahasti, A. Dailamy, P. Mali

This paper reprograms AAV tropism by displaying tiling peptides of receptor-ligands, identifying variants with improved tissue transduction and validated interactions.

bioRxiv · Sep 26, 2022 · PreprintBioengineering

Extensive in vitro and in vivo protein translation via in situ circularized RNAs

A. Kumar, N. Palmer, K. Miyasaki, E. Finburgh, Y. Xiang, A. Portell, A. Dailamy, A. Suhardjo, W. L. Chew, E. J. Kwon, P. Mali

This paper introduces in situ circularized RNAs (icRNAs) that enable extensive protein translation in vitro and in vivo, with applications in immunization, genome targeting, and protein engineering.

bioRxiv · Feb 11, 2022 · PreprintBioengineering

Robust RNA editing via recruitment of endogenous ADARs using circular guide RNAs

D. Katrekar, J. Yen, Y. Xiang, A. Saha, D. Meluzzi, Y. Savva, P. Mali

This paper introduces cadRNAs, circular guide RNAs that recruit endogenous ADARs for efficient and specific RNA editing in vitro and in vivo.

bioRxiv · Jan 12, 2021 · PreprintBioengineering